Studies On The Relativity Between Survivin Gene Promoter-625G/C Polymorphisms And Susceptibility Of Colorectal Cancer

Objective:To detect the genotype frequency and allele frequency distribution of the Survivin promoter-625G/C polymorphism in colorectal cancer (CRC) group and normal group.①Discuss the risk association between it’s polymorphism and colorectal cancer;②the Relation of the colorectal cancer clinical pathology parameters (location, gross type, histological type, degree of differentiation, depth of invasion, lymph node metastasis);③the Relation of the colorectal cancer prevalence and clinical detection of tumor markers (AFP, CEA, CA19-9, CA72-4);④the Relation of the prevalence of colorectal cancer plasma biochemical indexes (TC, LDL-C). Methods:With the colorectal cancer diagnosed patients and healthy people from The Affiliated Hospital of Luzhou Medical College of Sichuan Province were divided into colorectal cancer group and control group from August2009to November2011,collection of peripheral venous blood; extracted genomic DNA from the blood using phenol-chloroform extraction method. designed the mismatch primers of the Survivin promoter-625G/C site. Identification of Survivin promoter-625G/C gene type Using the PCR-RFLP technology in PCR-primer mismatch enzyme digestion method, and the agarose gel electrophoresis for. Tested the genotype HWE balance for the validation of selected survey data reliability.Used chi-square test for detection of colorectal cancer group and control group about the distribution difference between the genotype frequency and the allele frequency. Analysised the relation about CRC in patients with survivin promoter-625G/C locus genotype and clinical pathology parameters Using the chi-squared test. SPSS16.0software were used to analyze the relation of genotype of survivin promoter-625G/C and tumor clinical parameters using chi-square test. the relation of genotype frequencyclinical, clinical tumor markers and Clinical and biochemical indexes were used by T test. P<0.05have statistically significant. Results:The colorectal cancer group and the control group matched in sex and age, no significant difference in the distribution. Spromoter-625G/C locus genotype frequency and allele frequencies between the colorectal cancer group and the control group were consistent with Hardy-Weinberg equilibrium. The colorectal cancer group (p>0.05); the control group (P>0.05). The colorectal cancer group and the control group-625G/C site GG, GC+CC genotype frequency distribution has significant difference(P<0.05, bilateral); the G, C allele frequency distribution has significant difference(P<0.05, bilateral). The colorectal cancer-625G/C site GG, GC+CC genotype frequencies in different tumor sites (colon, rectum) had no significant difference (P>0.05, bilateral); in different tumor types(generally ulcer type, protuberant type) without significant difference (P>0.05, bilateral); in different tumor size (≥3cm,<3cm), there was no significant difference,(p>0.05, bilateral); in different histological type of tumor(adenocarcinoma, mucinous adenocarcinoma), there was no significant difference,(P>0.05, bilateral); in different neoplasms adenocarcinoma differentiation(well differentiate, middle-poorly differentiated), there was no significant difference,(P>0.05, bilateral); in different depth of tumor invasion (not yet reached full thickness, full thickness), there was no significant difference(P>0.05, bilateral); in tumor lymph node metastasis(without metastasis, metastasis), there was no significant difference (P>0.05, bilateral). AFP of colorectal cancer patients in the colorectal cancer survivin promoter-625G/C site GG, GC+CC genotype was no of significant difference (P>0.05,bilateral); CEA has no significant difference (P>0.05, bilateral); CA19-9has no significant difference(p>0.05, bilateral); CA72-4has no significant difference(p>0.05, bilateral). Patients with colorectal cancer-625G/C site GG, GC+CC genotype TC value difference has statistics significance (P<0.05); LDL-C value difference has statistics significance (P<0.05). Conclusion:1.Survivin promoter-625G/C polymorphism and colorectal cancer susceptibility have correlation.-625C is the risk loci of the colorectal cancer and-625G as protective site.2. The survivin promoter-625G/C sites gene polymorphism and clinical pathological parameters (site, gross type, histological type, differentiation, invasion depth, lymph node metastasis) in colorectal cancer are independent.3.Survivin promoter region of the-625G/C site gene polymorphism has nothing to do with biochemical indicators of colorectal cancer (AFP, CEA, CA19-9,CA72-4).4.Survivin promoter region of the-625G/C genes polymorphism in patients with colorectal cancer has something to do with clinical biochemical indicators of lipid (LDL-C、TC). And survivin promoter region of the-625G/C genes polymorphism in patients with colorectal cancer may be a TC and LDL-C level of risk factor levels.